Short-term eplerenone for treatment of chronic central serous chorioretinopathy; a prospective study

• Published in: International journal of retina and vitreous Vol. 5; no. 1; p. 39
• Main Authors: Moein, Hamid-Reza, Bierman, Lauren W, Novais, Eduardo A, Moreira-Neto, Carlos, Baumal, Caroline R, Rogers, Adam, Duker, Jay S, Witkin, André J
• Format: Journal Article
• Language: English
• Published: England BioMed Central 09.09.2019; BMC
• Subjects: Central serous chorioretinopathy; Eplerenone; Family medical history; Flow velocity; Lasers; Mineralocorticoid inhibitors; Original; Patients; Potassium; Studies; Tomography; Eplerenone; Mineralocorticoid inhibitors; Central serous chorioretinopathy
• ISSN: 2056-9920; 2056-9920
• DOI: 10.1186/s40942-019-0190-y

Increased mineralocorticoid activity is one of the plausible causes of chronic central serous chorioretinopathy (CSCR) and mineralocorticoid inhibitors such as eplerenone have been investigated as its potential therapy. This study investigates the short-term safety and efficacy of oral eplerenone in patients with chronic CSCR. Prospective study of 13 eyes of 13 patients with the diagnosis of chronic CSCR. All patients received eplerenone 50 mg/day for 4 weeks. Enhanced depth imaging optical coherence tomography (OCT) was obtained. Best corrected visual acuity (BCVA), and OCT parameters including sub retinal fluid (SRF), choroidal thickness (CT) and central macular thickness (CMT), were measured manually. The mean SRF height decreased slightly at 1-month follow-up as compared to baseline, but the change was not statistically significant (94.18 ± 17.53 vs. 113.15 ± 18.69; p = 0.08). Subfoveal CT and CMT was significantly reduced as compared to baseline (6.6% [p = 0.002] and 7.05% [p = 0.04], respectively). The BCVA did not change significantly (20/28 vs. 20/30 [p = 0.16]). This study suggests that oral eplerenone may be used as a safe and potentially effective treatment in chronic CSCR, however there are minimal short-term effects on subretinal fluid or visual acuity therefore therapeutic trials longer than one month are necessary to test its benefits. Clinicaltrials.gov identification number: NCT01822561. Registered 3/25/13, https://clinicaltrials.gov/ct2/show/study/NCT01822561.